1638153-78-2
Chemical Structure
SH-11037
- CAS No.: 1638153-78-2
- Formula:C34H39NO10
- Molecular Weight:621.67
InChIKey: WNDLJGVBWVLFKK-WCSIJFPASA-N
SMILES: COC1=C2C(OCC(C2=O)CC3=CC(OC([C@@H](NC(OC(C)(C)C)=O)CC4=CC=CC=C4)=O)=C(C=C3)OC)=CC(OC)=C1OC
Biological Activity: SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SH-11037 | SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Basavarajappa HD, et al. Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. J Med Chem. 2015;58(12):5015-5027. [Content Brief]
- [2]. Kim EY, et al. Mouse Pharmacokinetics and In Vitro Metabolism of SH-11037 and SH-11008, Synthetic Homoisoflavonoids for Retinal Neovascularization. Pharmaceutics. 2022;14(11):2270. Published 2022 Oct 24. [Content Brief]
- [3]. Sulaiman RS, et al. Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic Target for Ocular Neovascularization. ACS Chem Biol. 2018 Jan 19;13(1):45-52. [Content Brief]
- [4]. Sulaiman RS, et al. A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy. Sci Rep. 2016 May 5;6:25509. [Content Brief]
Keywords
